Clinical Trial

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Study acronym: TAL-T
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection. To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-04.
Trial Details
NCT Number NCT06302062
Lead Sponsor Guangzhou FineImmune Biotechnology Co., LTD.
Conditions Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
Enrollment 23 participants
Start Date 2023-06-06
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-03